RNXT RenovoRx, Inc.
Price Chart
Executive Summary
RenovoRx reported Q1 2026 revenue of $563,000, a 136% sequential increase from Q4 2025 and exceeding 50% of full-year 2025 revenue, driven by expansion to 16 active commercial cancer centers. The net loss widened to $3.5M from $2.4M a year ago, with SG&A costs rising as the company built commercial infrastructure. The company reiterated full-year 2026 revenue guidance of $3-4 million and ended the quarter with $12.4M in cash, sufficient to fund operations into at least H2 2027.
Key Financial Metrics
Actionable Insight
The strong sequential revenue growth and expanding commercial footprint are positive signals for a pre-profitability commercial-stage medtech. The reiterated $3-4M full-year guidance implies accelerating growth through 2026. However, the widening net loss and cash burn rate (~$3.5M/quarter) mean the $12.4M cash runway is about 3-4 quarters without additional financing. Watch for continued quarterly revenue acceleration and TIGeR-PaC enrollment completion in June as key catalysts.
Key Facts
- Q1 2026 revenue of $563,000, up 136% QoQ from Q4 2025 and 186% YoY from $197,000
- Active commercial cancer centers grew to 16 as of May 6, 2026, from 8 at end of 2025
- Net loss of $3.5M vs $2.4M in Q1 2025, driven by SG&A increase to $2.7M from $1.6M
- Cash and equivalents of $12.4M as of March 31, 2026, after $10M private placement in March
- Phase III TIGeR-PaC trial enrollment expected to close in June 2026, with final data anticipated in mid-to-late 2027
- Full-year 2026 revenue guidance reiterated at $3-4 million
Financial Impact
Revenue of $563K vs consensus $463K, a 21.6% beat. Net loss of $3.5M was wider than the $2.4M loss in Q1 2025, but in line with the company's investment phase.
Risk Factors
- Cash runway of ~3-4 quarters at current burn rate may require additional financing before H2 2027
- TIGeR-PaC trial results are binary and not expected until 2027; interim data is deferred
- Commercial adoption is still early — 16 active centers vs 36 target by year-end 2026
- S-3 shelf filed in April 2026 allows resale of up to 15.96M shares, creating potential overhang
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-224080 |
| Document: 0001193125-26-224080-index.html | 0001193125-26-224080 |
| Document: 0001193125-26-224080.txt | 0001193125-26-224080 |
| 8-K Data (Synthetic) | 0001193125-26-224080 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
Press Release
| $0.9160 $0.9210 | ▲ +0.55% | ▼ −0.54% | $0.8440 (−7.86%) |
|
May 19, 2026
25d ago
|
Press Release
| $0.8060 $0.9052 | ▲ +12.31% | ▲ +10.06% | $0.8440 (+4.71%) |
|
May 15, 2026
28d ago
|
10-K/A
| $0.7830 $0.9160 | ▲ +16.99% | ▲ +15.37% | $0.8440 (+7.79%) |
|
May 14, 2026
29d ago
|
8-K
| $0.8200 $0.8820 | ▲ +7.56% | ▲ +6.60% | $0.8440 (+2.93%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $0.8310 $0.9280 | ▲ +11.67% | ▲ +8.56% | $0.8440 (+1.56%) |
|
Apr 28, 2026
6w ago
|
EFFECT
| $0.8400 $0.9280 | ▲ +10.48% | ▲ +8.78% | $0.8440 (+0.48%) |
|
Apr 16, 2026
8w ago
|
S-3
| $1.00 $0.8570 | ▼ −14.30% | ▼ −14.85% | $0.8440 (−15.60%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.03 $0.9490 | ▼ −7.86% | ▼ −9.26% | $0.8440 (−18.06%) |
|
Mar 30, 2026
10w ago
|
8-K
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access